Our projects
2. |
Scale-up of point-of-care testing strategies to enhance hepatitis C treatment among people who inject drugs: Modelling, affordability and cost-effectiveness analysis. |
Status
Completed
Year
2020
Named PI/Co-PI
Jason Grebley, Sophy Shih, Richard Gray, Virginia Wiseman
Other investigators
A. Kwon, P. Vickerman, N. Martin
Lead EMCR
Amy Kwon
# of EMCRs
1
Regional setting
Australia
Discipline
Health Economics, Modelling
The Problem
Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. However, conventional lab-based testing for HCV requires multiple visits to health facilities that contributes to low treatment uptake in key populations.
The Solution
Cost-effectiveness analyses were undertaken from the perspective of Australian Governments as funders by modelling point-of-care testing strategies compared to standard-of-care in needle and syringe programs, drug treatment clinics, and prisons. The modelling results suggest testing strategies combining point-of-care HCV antibody and RNA testing has potential to optimise health outcomes and improve efficiency.
Related Publications
Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis.
Lancet Reg Health West Pac. 2023
Shih STF, Cheng Q, Carson J, Valerio H, Sheehan Y, Gray RT, Cunningham EB, Kwon JA, Lloyd AR, Dore GJ, Wiseman V, Grebely J. More info